Milestone Pharmaceuticals/$MIST
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
Ticker
$MIST
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Montreal, Canada
Employees
33
ISIN
CA59935V1076
Website
MIST Metrics
BasicAdvanced
$119M
-
-$0.78
0.86
-
Price and volume
Market cap
$119M
Beta
0.86
52-week high
$2.75
52-week low
$0.63
Average daily volume
718K
Financial strength
Current ratio
4.665
Quick ratio
4.431
Long term debt to equity
-898.987
Total debt to equity
-907.839
Interest coverage (TTM)
-14.31%
Profitability
EBITDA (TTM)
-52.045
Management effectiveness
Return on assets (TTM)
-41.29%
Return on equity (TTM)
-307.27%
Valuation
Price to book
-19.4
Price to tangible book (TTM)
-19.4
Price to free cash flow (TTM)
-3.497
Free cash flow yield (TTM)
-28.59%
Free cash flow per share (TTM)
-51.18%
Growth
Earnings per share change (TTM)
-36.28%
3-year earnings per share growth (CAGR)
-9.39%
What the Analysts think about MIST
Analyst ratings (Buy, Hold, Sell) for Milestone Pharmaceuticals stock.
MIST Financial Performance
Revenues and expenses
MIST Earnings Performance
Company profitability
MIST News
AllArticlesVideos
Milestone Pharmaceuticals Submits Response to the FDA's CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting
GlobeNewsWire·1 week ago
Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
GlobeNewsWire·1 month ago
US FDA declines to approve Milestone Pharma's heart rhythm nasal spray
Reuters·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Milestone Pharmaceuticals stock?
Milestone Pharmaceuticals (MIST) has a market cap of $119M as of June 25, 2025.
What is the P/E ratio for Milestone Pharmaceuticals stock?
The price to earnings (P/E) ratio for Milestone Pharmaceuticals (MIST) stock is 0 as of June 25, 2025.
Does Milestone Pharmaceuticals stock pay dividends?
No, Milestone Pharmaceuticals (MIST) stock does not pay dividends to its shareholders as of June 25, 2025.
When is the next Milestone Pharmaceuticals dividend payment date?
Milestone Pharmaceuticals (MIST) stock does not pay dividends to its shareholders.
What is the beta indicator for Milestone Pharmaceuticals?
Milestone Pharmaceuticals (MIST) has a beta rating of 0.86. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.